BEAM News and Press, Beam Therapeutics Inc. From 08/29/23

2023-08-29 08:06:00 ET More on Apellis Sticking With Apellis: Navigating Syfovre's Safety Measures In A Volatile Market Apellis Pharmaceuticals, Inc. ( APLS ) Q2 2023 Earnings Call Transcript Apellis Pharmaceuticals, Inc. 2023 Q2 - Results - Earnings Call Present...

2023-08-08 07:51:36 ET Beam Therapeutics press release ( NASDAQ: BEAM ): Q2 GAAP EPS of -$1.08 beats by $0.31 . Revenue of $20.12M (+20.8% Y/Y) beats by $3.27M . Beam expects that its cash, cash equivalents and marketable securities as of June 30, 2023, will en...

BEACON Trial of BEAM-101 in Sickle Cell Disease Progressing with Consented Patients Projected to Fill Sentinel Cohort and to Initiate Expansion Cohort First Patient Consented in Phase 1/2 Trial of BEAM-201 in T-ALL/T-LL and Expected to be Dosed in The Third Quarter of 2023 Compa...

2023-07-28 16:23:26 ET Summary Beam Therapeutics is a leading biotech firm focused on precision genetic medicine with applications in hematology, immunology, oncology, and genetic diseases. Beam's stock assessment shows mixed performance and valuation metrics, with concerns about ...

2023-07-19 01:15:36 ET Summary ARK Invest's 13F portfolio value increased by approximately 4% from $14.55B to $15.10B in Q2 2023, with holdings increasing from 221 to 222. The firm established a new 0.69% stake in Palantir Technologies while increasing stakes in Coinbase Global, U...

2023-07-07 14:35:37 ET Summary Amidst a furious rally in growth stocks, the ARK Innovation ETF has somehow been left out. Fund manager Cathie Wood has famously missed out on the bulk of Nvidia Corporation profits, but that is not the only issue here. I discuss why I like a lot...

2023-05-24 07:24:00 ET Novo Nordisk ( NVO ) has partnered with U.S.-based biotech Life Edit Therapeutics to discover and develop gene editing treatments targeted at rare and cardiometabolic diseases, the companies announced Wednesday. Under the partnership, two companies will focus ...

2023-05-21 08:23:00 ET Beam Therapeutics (NASDAQ: BEAM) is exactly the kind of innovative biotech business that maverick growth stock investor Cathie Wood craves. Her shares are worth $210.5 million, and they account for around 3% of Wood's Ark Innovation ETF (NYSEMKT: ARKK) ...

2023-05-20 08:00:00 ET Summary Beam is a leader in base editing and has strong lab data. It has a huge amount of cash and a major deal with Pfizer. Next year, Beam will produce first human data. I covered Beam Therapeutics (BEAM) in April last year, when the stock ha...

2023-05-16 05:50:00 ET Cathie Wood looks for stocks that are leading innovators. But the stocks that fit that mold aren't always leaders when it comes to delivering huge returns over the short term. On the contrary, quite a few of the stocks in Wood's Ark Invest portfolios have been big...